Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
New England Journal of Medicine · 18.06.2026 · 394 (23) · 2382-2383
DOI: 10.1056/nejmc2605751 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 18.06.2026. Verfasst von Christof Vulsteke und 1 weiteren Autor:innen. Beteiligte Einrichtung: AZ Maria Middelares, Ghent, Belgium. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
To the Editor: Vulsteke et al. (April 2 issue) 1 report a substantial 2-year event-free survival with perioperative enfortumab vedotin and pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer, as well as a remarkably high percentage of those who had a pathological complete response. Of note, the magnitude of pathological complete response suggests that many patients may have minimal residual disease after neoadjuvant therapy alone. Given the 100% incidence of adverse events and the high incidence of toxic effects of grade 3 or higher, the uniform addition of an adjuvant phase may not be justified. Circulating tumor DNA (ctDNA) provides a . . .
Autor:innen und Institutionen
- AZ Maria Middelares, Ghent, Belgium.
- Karolinska University Hospital, Stockholm.
Zitieren
APA
Vulsteke, C., & Ullén, A. (2026). Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine, 394(23), 2382-2383. https://doi.org/10.1056/nejmc2605751
Vancouver
Vulsteke C, Ullén A. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. New England Journal of Medicine. 2026;394(23):2382-2383. doi:10.1056/nejmc2605751
BibTeX
@article{Vulsteke2026,
author = {Vulsteke, Christof and Ullén, Anders},
title = {Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {23},
pages = {2382--2383},
doi = {10.1056/nejmc2605751}
}
EUVIMED